Gildi - lifeyrissjodur Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002108148

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedIndustrials TiltHigh Turnover how tags are computed

Q1 2026 Q4 2025

Q1 2026 · 2 positions · Total reported value $197.19M · Top-10 concentration 100.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 100.0% · 0 new · 2 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q1 2026 13F filing, Gildi - lifeyrissjodur disclosed 2 equity positions with a combined reported value of $197.19M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Industrials Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were JBTM ($132.87M), OCS ($64.32M). By sector, the heaviest allocations are Industrials 67.4%, Health Care 32.6%. Versus the prior quarter, allocation shifted toward Health Care (+9.9pp) and away from Industrials (-9.9pp).

Versus the prior quarter, Gildi - lifeyrissjodur opened 0 new positions, trimmed 2 and fully exited 0, a turnover rate of 100.0% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Gildi - lifeyrissjodur buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Gildi - lifeyrissjodur is an SEC-registered 13F filer. As of Q1 2026 it reported 2 US equity positions with a combined value of $197.19M. HoldingsHub carries 2 quarters of its filings (Q4 2025–Q1 2026).

Portfolio Structure

  • 2 positions · $197.19M reported value (Q1 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: JBTM (JBT MAREL CORPORATION) at 67.4%
  • Average position size: $98.59M

Sector Tilt

  • Industrials 67.4%
  • Health Care 32.6%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q1 2026: 2 reduced

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund's rebalancing appears to reflect a conservative approach with a focus on reducing positions in its holdings. The reduction in shares in both top holdings suggests a cautious stance amidst market uncertainty. 2. Key Moves: - Reduced Positions: The fund reduced its position in JBT MAREL CORPORATION (JBTM) by 3.8% quarter-over-quarter (QoQ) and in OCULIS HOLDING AG (OCS) by 0.7% QoQ. - No New Positions: The fund did not add any new positions this quarter. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be leaning towards a passive approach, as it did not add any new positions and reduced existing ones. - Sector Bias: The holdings are concentrated in Industrials and Health Care sectors, which could indicate a preference for cyclical industries. - Risk Appetite: The risk appetite appears conservative, given the reduction in positions and sectors that tend to be more volatile. 4. Per-Holding One-Liner: - JBTM (JBT MAREL CORPORATION): A manufacturer of automated handling equipment and software solutions for the food and beverage industry. 'Unverified' - OCS (OCULIS HOLDING AG): A biopharmaceutical company focused on developing therapies for rare eye diseases. 'Unverified' 5. One-Sentence Style Summary: The fund's rebalancing this quarter reflects a conservative stance, reducing positions in key holdings and maintaining a focus on Industrials and Health Care sectors, indicating a preference for stability and cyclical industries.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Industrials 67.4%
Health Care 32.6%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.07M $132.87M 67.38%
67.38%
Reduce
2 2.43M $64.32M 32.62%
32.62%
Reduce

FAQ

What did Gildi - lifeyrissjodur buy in 2026-Q1?

In its 2026-Q1 13F filing, Gildi - lifeyrissjodur reported 2 equity positions worth $197.19M in aggregate; its largest disclosed positions were JBTM ($132.87M), OCS ($64.32M).

How large is Gildi - lifeyrissjodur's portfolio?

Gildi - lifeyrissjodur reported $197.19M of long equity holdings across 2 positions as of 2026-Q1. Top-10 holdings account for 100.0% of reported value.

What is Gildi - lifeyrissjodur's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Industrials Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/gildi-lifeyrissjodur/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →